GLP-1 Weight-Loss Drugs May Guard Against Dementia

SUMMARY: Recent research suggests that GLP-1 receptor agonists—drugs like Ozempic used to manage type 2 diabetes—may also help reduce the risk of dementia. Two new studies investigated how these and other glucose-lowering medications impact brain health. One study, led by researchers from the University of Galway, analysed data from 26 clinical trials (over 160,000 participants) and found that GLP-1RAs were linked to a 45% lower risk of all-cause dementia and cognitive decline. However, they had no effect on specific dementia types like Alzheimer’s, vascular, or Lewy body dementia. A second, larger study from the University of Florida looked at nearly 400,000 patient records. It found that both GLP-1RAs and SGLT2 inhibitors were associated with reduced risks of Alzheimer’s and related dementias, compared to other diabetes drugs. Despite these promising findings, experts caution that limitations like short follow-up periods, broad drug classifications, and possible confounding factors mean more research is needed—especially focusing on newer, more potent drugs like semaglutide.

This could be great news, but wasn’t there also another paper recently that found Ozempic contributes to blindness?

Important to note from the study these articles are based on:

# “As this study was observational and therefore prone to residual confounding and informative censoring, the effect size could have been overestimated. Randomised controlled trials are needed to confirm these findings.” [[1]](https://www.bmj.com/content/386/bmj-2024-079475)

This article headline is misleading and makes an unfounded leap by suggesting that Ozempic may prevent dementia based on a study that doesn’t even involve GLP-1 receptor agonists like Ozempic. **The article cites another article than then cites a study focused on SGLT-2 inhibitors and, while it found a statistical association with reduced dementia risk, it was observational in nature, meaning it shows correlation, not causation.** Even within that study, the authors explicitly caution that the effect could be overestimated due to residual confounding and that randomized controlled trials are needed for confirmation. Citing this indirectly, especially across drug classes, stretches the data beyond its limits. It’s speculative at best and misleading at worst, giving the impression of proven benefit where none has been established. I bring this up because there is great financial incentive to present Ozempic as some miracle cure all drug, hence the uptick in articles with headlines like this.